AI summary · may contain errors
Spatial profiling of resected non-small cell lung cancer tumors and lymph nodes identified immune subtypes and a gene signature linked to improved outcomes.
Moving in Journal of Thoracic Oncology, Clinical Cancer Research, The Lancet Respiratory Medicine, American Journal of Respiratory and Critical Care Medicine, Annals of Oncology, Journal of Clinical Oncology, JAMA Oncology and European Respiratory Journal.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Spatial profiling of resected non-small cell lung cancer tumors and lymph nodes identified immune subtypes and a gene signature linked to improved outcomes.
AI summary · may contain errors
MTAP loss is among the most common potentially targetable driver mutations in non-small cell lung cancer (NSCLC), supporting ongoing early-phase trials.
AI summary · may contain errors
In resectable non-small cell lung cancer, major pathologic response is linked to spatial enrichment of T- and B-cell activation pathways and CD8+ T-cell infiltration, with an MPR rate of 37.5%.
AI summary · may contain errors
MTAP-deleted advanced non-small cell lung cancer shows worse progression-free survival than MTAP wild-type on anti-PD-(L)1–based regimens, with hazard ratios up to 1.89.
AI summary · may contain errors
In 365 patients with non-small cell lung cancer harboring KRAS Q61 mutations, median overall survival was 12.3 months, with first-line immunotherapy linked to longer survival.
AI summary · may contain errors
Among screening-eligible current smokers in the NLST, low-dose CT screening is linked to 12% lower lung cancer mortality versus chest radiography (HR 0.88, 95% CI 0.79–0.97).
AI summary · may contain errors
AI-guided geographical targeting with MATCH-AI increased camp positivity yield for bacteriologically confirmed tuberculosis in Pakistan in a validated per-protocol analysis (32% higher; 1·32, 1·12–1·54; p<0·0001).
AI summary · may contain errors
Baseline PD-L1 and TP53 combined with TSG are linked to very-early progression on first-line osimertinib monotherapy in EGFR-mutant NSCLC, with PD-L1 TPS showing the strongest signal.
AI summary · may contain errors
Ruzaltatug rezetecan significantly improved BICR-assessed progression-free survival versus chemotherapy in 498 Chinese patients with EGFR-mutated advanced NSCLC after EGFR TKI progression.
AI summary · may contain errors
Dose interruptions of four or more consecutive days in US FDA trial populations of NSCLC with EGFR mutations are more often linked to higher progression or death risk than dose reductions.
AI summary · may contain errors
HB0025 plus chemotherapy produced confirmed objective response rates of 36.4% and 57.1% in previously untreated driver variant-negative nonsquamous advanced NSCLC, with manageable toxicity.
AI summary · may contain errors
In a real-world cohort of 265 U.S. patients with small cell lung cancer, tarlatamab achieved a 52.6% disease control rate and median rw-PFS of 2.3 months.
AI summary · may contain errors
Neoadjuvant perioperative ivonescimab plus chemotherapy in resectable non-small cell lung cancer achieved a 70.1% major pathological response rate (47/67), meeting the primary endpoint.
AI summary · may contain errors
Consolidation durvalumab after concurrent chemoradiotherapy in limited-stage small-cell lung cancer is linked to lower extrathoracic progression (20.1% vs 30.1%) and longer time to progression or death.
AI summary · may contain errors
SABR is linked to higher 3-year all-cause mortality than surgical resection in eligible early-stage NSCLC patients, with 30.3% vs 21.6% mortality.
AI summary · may contain errors
In resected lung adenocarcinoma, TP53 and KRAS mutations predict worse stage I overall survival (HR 2.49 and 1.57), while stage I EGFR mutations predict better outcomes (HR 0.59).
AI summary · may contain errors
In stage III, unresectable PD-L1–positive NSCLC after platinum-based concurrent chemoradiation, tiragolumab plus atezolizumab did not improve IRF-assessed PFS (19.4 vs 16.6 months).
Journals this month
Topics moving, week to 17 Nov 2026
By field